ArticlePeerJ2020
Immunoglobulin superfamily member 10 is a novel prognostic biomarker for breast cancer.
Article in PeerJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- IGSF10 regulates osteogenesis and osteoclastogenesis via a noncanonical EGFR-STAT1 signaling axis to promote skeletal regeneration.Bone research · 2026Article
- Exploratory Machine Learning and Omics Integration in the Search for Biomarkers of Papillary Thyroid Cancer.Biology · 2026Article
- High Expression of IGSF10 Confers an Inhibitory Effect on the Progression of Lung Adenocarcinoma.Journal of cellular and molecular medicine · 2025Article
- IGSF10 is a RET antagonist regulating Ewing sarcoma growth and GnRH neuron migration.Cell reports · 2025Article
- Article
- Independent and interactive roles of hirudin and HMGB1 interference in protecting renal function by regulating autophagy, apoptosis, and kidney injury in chronic kidney disease.European journal of histochemistry : EJH · 2025Article
- Identification of candidate biomarkers correlated with the pathogenesis of breast cancer patients.Scientific reports · 2025Article
- EDNRA regulates the tumour immune environment and predicts the efficacy and prognosis of cancer immunotherapy.Journal of cellular and molecular medicine · 2024Article
- Bioinformatic Identification of Signaling Pathways and Hub Genes in Vascular Dementia.Actas espanolas de psiquiatria · 2024Article
- Establishment of a prognostic risk model for osteosarcoma and mechanistic investigation.Frontiers in pharmacology · 2024Article
- Association ofInternational journal of molecular sciences · 2023Article
- IGJ suppresses breast cancer growth and metastasis by inhibiting EMT via the NF‑κB signaling pathway.International journal of oncology · 2023Article
- Identification of key somatic oncogenic mutation based on a confounder-free causal inference model.PLoS computational biology · 2022Article
- Orthodenticle homeobox OTX1 is a potential prognostic biomarker for bladder cancer.Bioengineered · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunoglobulin superfamily member 10 (IGSF10) is a member of the immunoglobulin superfamily that is expressed at high levels in both the gallbladder and ovary. Currently, the role and possible mechanism of IGSF10 in breast cancer remain unclear.
methodBy applying real-time quantitative polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC), the expression of IGSF10 in breast cancer cells and tissues was detected. We collected the clinical information from 700 patients with breast cancer in The Cancer Genome Atlas (TCGA), and analyzed the relationship between IGSF10 expression and the clinicopathological features and survival outcomes of these patients. The potential mechanisms and pathways associated with IGSF10 in breast cancer were explored by performing a gene set enrichment analysis (GSEA).
resultsAccording to TCGA data, qRT-PCR and IHC experiments, levels of the IGSF10 mRNA and protein were significantly decreased in breast cancer tissues. IGSF10 expression was significantly correlated with age, tumor size, and tumor stage. Moreover, shorter overall survival (OS) and relapse-free survival (RFS) correlated with lower IGSF10 expression, according to the survival analysis. The multivariate analysis identified that IGSF10 as an independent prognostic factor for the OS (hazard ratio (HR) = 1.793, 95% confidence interval (CI) [1.141-2.815],
conclusionsThis study revealed a clear relationship between IGSF10 expression and the tumorigenesis of breast cancer for the first time. Therefore, further studies are needed to understand the mechanism of IGSF10 in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.